A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

Bioseeker, November 2010, Pages: 777

This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. BioSeeker has applied its unique drug assessment methodology to stratify the melanoma pipeline and discern the level of competition in fine detail.

Major Findings from this report:

- The identified competitive landscape of melanoma drugs is split between the 55% which have unique drug target strategies and the other part which have head-to-head target competing melanoma drugs in 32 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the melanoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, BARF and TUBB.
- Nine out of ten drug target strategies in Phase II development are new to melanoma drugs and at the same time the greatest numbers of new target strategies are found in Phase II (27%) and Phase I development (19%).
- Small molecules, antibodies and proteins are the dominating compound strategies of melanoma drugs, which represent almost three quarters of the entire pipeline. Cell therapy based melanoma drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of melanoma drugs.
- The highest number of described drug target strategies of melanoma drugs belongs to Pfizer, Novartis, Hoffmann-La Roche and Bristol-Myers Squibb.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any melanoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary

2 About Cancer Highlights™
2.1 Cancer Focus Areas
2.2 Subscribe Today and Start Saving
2.2.1 Type of License
2.3 BioSeeker Group’s Oncology Team

3 Methodology
3.1 Cancer Highlights’™ Five Pillar Drug Assessment

4 Table of Contents
4.1 List of Figures
4.2 List of Tables

5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations

6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Targets of Cancer Vaccine Drugs
6.2.1 Acid Phosphatase Activity Targets
6.2.2 Carboxypeptidase Activity Targets
6.2.3 Catalytic Activity Targets
6.2.4 Cell Adhesion Molecule Activity Targets
6.2.5 Chaperone Activity Targets
6.2.6 Cofactor Binding Targets
6.2.7 Complement Activity Targets
6.2.8 Cytokine Activity Targets
6.2.9 DNA Binding Targets
6.2.10 DNA Topoisomerase Activity Targets
6.2.11 DNA-directed DNA Polymerase Activity Targets
6.2.12 Growth Factor Activity Targets
6.2.13 Heat Shock Protein Activity Targets
6.2.14 Hormone Activity Targets
6.2.15 Isomerase Activity Targets
6.2.16 Kinase Binding Targets
6.2.17 Kinase Regulator Activity Targets
6.2.18 Metallopeptidase Activity Targets
6.2.19 MHC Class I Receptor Activity Targets
6.2.20 Molecular Function Unknown Targets
6.2.21 Oxidoreductase Activity Targets
6.2.22 Peptidase Activity Targets
6.2.23 Peptide Hormone Targets
6.2.24 Protein Binding Targets
6.2.25 Protein Serine/Threonine Kinase Activity Targets
6.2.26 Protein-tyrosine Kinase Activity Targets
6.2.27 Receptor Activity Targets
6.2.28 Receptor Signaling Complex Scaffold Activity Targets
6.2.29 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
6.2.30 RNA-directed DNA Polymerase Activity Targets
6.2.31 Serine-type Peptidase Activity Targets
6.2.32 T Cell Receptor Activity Targets
6.2.33 Transcription Factor Activity Targets
6.2.34 Transcription Regulator Activity Targets
6.2.35 Transmembrane Receptor Activity Targets
6.2.36 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.37 Transporter Activity Targets
6.2.38 Other Targets
6.3 The Cancer Genome Project and Targets of Cancer Vaccine Drugs
6.3.1 Targets of Cancer Vaccine Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Structure-based Drug Design in Cancer Vaccine Therapeutics is Stimulated by Available Structure Data on Biological Targets
6.5 Target-Target Interactions among Identified Targets of Cancer Vaccine Drugs
6.6 The Drug-Target Competitive Landscape
6.7 Protein Expression Levels of Identified Targets of Cancer Vaccine Drugs
6.8 Pathway Assessment of Caner Vaccine Drugs
6.8.1 Tools for Analysis of Cancer Pathways
6.8.2 Pathway Assessment

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development
7.1 Marketed: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.5 Preclinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.6 No Development Data: New and Unique Drug Target Strategies of Cancer Vaccine Drugs
7.7 Drug Target Strategies of Suspended, Discontinued or Terminated Cancer Vaccine Drugs
7.8 Target Strategy Profiles of Cancer Vaccine Drugs
7.8.1 Marketed
7.8.2 Phase III
7.8.3 Phase II
7.8.4 Phase I
7.8.5 Preclinical
7.8.6 Suspended
7.8.7 Ceased
7.9 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy
8.1 Small Molecules
8.1.1 Background
8.1.2 Target Strategies of Small Molecule Drugs
8.2 Peptide & Protein Drugs
8.2.1 Background
8.2.2 Target Strategies of Peptide and Protein Drugs
8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Target Strategies of Antibody Drugs
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Target Strategies of Nucleic Acid Drugs
8.5 Cell & Gene Therapy
8.5.1 Background
8.5.2 Target Strategies of Cell and Gene Therapy Drugs
8.6 Compound Strategies based on Sub-Cellular Localization of Drug Targets

9 Selecting Cancer Indications for Cancer Vaccine Drugs
9.1 Acute Lymphocytic Leukemia
9.2 Acute Myelogenous Leukemia
9.3 Anal Dysplasia
9.4 B-cell Lymphoma
9.5 Bladder Cancer
9.6 Bone Cancer
9.7 Brain Cancer
9.8 Breast Cancer
9.9 Cancer (general)
9.10 Cervical Cancer
9.11 Chemotherapy-induced Bone Marrow Injury (general)
9.12 Cervical Dysplasia
9.13 Chronic Myelogenous Leukemia
9.14 Colorectal Cancer
9.15 Gastrointestinal Cancer (general)
9.16 Gastrointestinal Stomach Cancer
9.17 Head and Neck Cancer
9.18 Hematological Cancer (general)
9.19 Leukemia (general)
9.20 Liver Cancer
9.21 Lung Cancer (general)
9.22 Lymphoma (general)
9.23 Melanoma
9.24 Mesothelioma
9.25 Myelodysplastic Syndrome
9.26 Myeloma
9.27 non-Hodgkin's Lymphoma
9.28 Non-Small Cell Lung Cancer
9.29 Oesophageal Cancer
9.30 Osteo Sarcoma
9.31 Ovarian Cancer
9.32 Pancreatic Cancer
9.33 Prostate Cancer
9.34 Renal Cancer
9.35 Skin Cancer (general)
9.36 Small Cell Lung Cancer
9.37 Soft Tissue Sarcoma
9.38 Solid Tumor
9.39 Squamous Cell Cancer
9.40 Thyroid Cancer
9.41 Unspecified Cancer Indication
9.42 Vaccine adjunct

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator
10.1 Competitive Fall-Out Assessment
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
10.3 AC Immune
10.4 Adaptimmune
10.5 Aduro BioTech
10.6 Advaxis
10.7 Aida Pharmaceuticals
10.8 Akela Pharma
10.9 AlphaVax
10.10 Apthera
10.11 Astellas
10.12 AstraZeneca
10.13 AVI BioPharma
10.14 Bavarian Nordic
10.15 Bellicum Pharmaceuticals
10.16 Biogen Idec
10.17 Biostar
10.18 BioVex
10.19 Cadila
10.20 Cancer Research Technology
10.21 Cell Genesys
10.22 Celldex Therapeutics
10.23 CG Therapeutics
10.24 Cosmo Pharmaceuticals
10.25 CSL
10.26 Dendreon
10.27 DeveloGen
10.28 Eisai
10.29 Eli Lilly
10.30 EntreMed
10.31 Epeius Biotechnologies
10.32 Generex
10.33 GenOdyssee Pharmaceuticals
10.34 GENTICEL
10.35 Geron
10.36 GlaxoSmithKline
10.37 Gliknik
10.38 GlobeImmune
10.39 Gradalis
10.40 Ichor Medical Systems
10.41 Idera Pharmaceuticals
10.42 ImmunoCellular Therapeutics
10.43 ImmunoFrontier
10.44 Immunotope
10.45 Innate Pharma
10.46 Inovio
10.47 Introgen Therapeutics
10.48 ISA Pharmaceuticals
10.49 Johnson & Johnson
10.50 Medical Marketing International
10.51 MediGene
10.52 Menarini
10.53 Merck KGaA
10.54 Micromet
10.55 MolMed
10.56 Mologen
10.57 Nemod Biotherapeutics
10.58 Neovacs
10.59 NIH – US National Institute of Health
10.60 Non-industrial Sources
10.61 Northwest Biotherapeutics
10.62 NovaRx
10.63 OncoMune
10.64 OncoTherapy Science
10.65 Oncothyreon
10.66 Oncovir
10.67 Onyvax
10.68 Oxford BioMedica
10.69 Pepscan Systems
10.70 Pepscan Therapeutics
10.71 Pfizer
10.72 Pharmexa
10.73 Prima Biomed
10.74 Progenics Pharmaceuticals
10.75 Protherics
10.76 Radient Pharmaceuticals
10.77 Receptor BioLogix
10.78 responsif
10.79 Sanofi-Aventis
10.80 Scancell
10.81 SciClone Pharmaceuticals
10.82 TapImmune
10.83 Therion Biologics
10.84 Transgene
10.85 United Biomedical
10.86 Vaccinex
10.87 Vaxil BioTherapeutics
10.88 Vaxon Biotech
10.89 VaxOnco
10.90 Vectura
10.91 Vical
10.92 Viragen
10.93 Virionics
10.94 ViroMed
10.95 Zensun
11 Disclaimer
12 Drug Index
13 Company Index

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Cancer Vaccine Drugs
Figure 2: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Large Cluster
Figure 3: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Smaller Clusters
Figure 4: Head-to-Head Targeting Competitive Landscape of Cancer Vaccine Drugs
Figure 5: Distribution of Compound Strategies among Cancer Vaccine Drugs
Figure 6: Primary Sub-cellular Localization of Drug Targets

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development
Table 3: Head to Head Target Competition among Cancer Vaccine Drugs

Table 4: Overview of Drug Target Strategy Themes
Table 5: Terminally Ceased Targets of Cancer Vaccine Drugs
Table 6: Official Gene Name to Target Profle
Table 7: Targets of Cancer Vaccine Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 8: Identity of Cancer Vaccine Drug Targets with Available Biological Structures
Table 9: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs
Table 10: Available Protein Expression Profiles of Cancer Vaccine Drugs Targets
Table 11: Pathway Summary
Table 12: Drug Targets without any Identified Assigned Pathways
Table 13: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets
Table 14: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets
Table 15: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
Table 17: Top Competitive Target Strategies of Cancer Vaccine Drugs
Table 18: New and Unique Target Strategies of Marketed Cancer Vaccine Drugs
Table 19: New and Unique Target Strategies in Phase III Clinical Development of Cancer Vaccine Drugs
Table 20: New and Unique Target Strategies in Phase II Clinical Development of Cancer Vaccine Drugs
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs
Table 22: New and Unique Target Strategies in Phase I Clinical Development of Cancer Vaccine Drugs
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs
Table 24: New and Unique Target Strategies in Preclinical Development of Cancer Vaccine Drugs
Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs
Table 26: New and Unique Target Strategies in Unknown Developmental Stage of Cancer Vaccine Drugs
Table 27: The Competition Through Close Mechanistic Approximation Between Cancer Vaccine Drugs with No Developmental Data
Table 28: Target Strategies of Suspended, Discontinued and Terminated Cancer Vaccine Drugs
Table 29: Connecting Target Strategy with Its Identification Number
Table 30: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs
Table 31: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs
Table 32: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccines Drugs
Table 33: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccines Drugs
Table 34: Overview of the Competitive Landscape of Peptide Based Cancer Vaccines Drugs
Table 35: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccines Drugs
Table 36: Pursued Target Strategies of Peptide Based Cancer Vaccines Drugs
Table 37: Overview of the Competitive Landscape of Protein Based Cancer Vaccines Drugs
Table 38: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccines Drugs
Table 39: Pursued Target Strategies of Protein Based Cancer Vaccines Drugs
Table 40: Overview of the Competitive Landscape of Antibody Based Cancer Vaccines Drugs
Table 41: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccines Drugs
Table 42: Pursued Target Strategies of Antibody Based Cancer Vaccines Drugs
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccines Drugs
Table 44: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccines Drugs
Table 45: Potential Forms of Cell Therapy
Table 46: Vectors in Gene Therapy
Table 47: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccines Drugs
Table 48: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs
Table 49: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccines Drugs
Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccines Drugs
Table 52: Pursued Target Strategies of Gene Therapy Based Cancer Vaccines Drugs
Table 53: Compound Strategies based on Sub-Cellular Localization of Cancer Vaccine Drug Targets
Table 54 Competitive Summary by Cancer Indication of Cancer Vaccine Drugs
Table 55: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia
Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia
Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia
Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma
Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer
Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer
Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer
Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer
Table 63: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general)
Table 65: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer
Table 66: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs
Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general)
Table 68: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia
Table 69: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs
Table 70: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia
Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer
Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs
Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general)
Table 74: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer
Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer
Table 76: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs
Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general)
Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general)
Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer
Table 80: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs
Table 81: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general)
Table 82: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs
Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general)
Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma
Table 85: The Competition through Close Mechanistic Approximation between Melanoma Drugs
Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma
Table 87: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome
Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma
Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma
Table 90: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer
Table 91: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs
Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer
Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma
Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer
Table 95: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs
Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer
Table 97: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs
Table 98: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer
Table 99: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs
Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer
Table 101: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs
Table 102: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general)
Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer
Table 104: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma
Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor
Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Cancer
Table 107: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer
Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication
Table 109: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs
Table 110: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Vaccine adjunct
Table 111: Example of a Competitive Fall-Out Table (Modified, Platelet glycoprotein 4 trageting drugs)
Table 112: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development
Table 113: AC Immune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 114: Adaptimmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 115: Aduro BioTech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 116: Advaxis’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 117: Aida Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 118: Akela Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 119: AlphaVax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 120: Apthera's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 121: Astellas’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 122: AstraZeneca's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 123: AVI BioPharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 124: Bavarian Nordic's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 125: Bellicum Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 126: Biogen Idec's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 127: Biostar's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 128: BioVex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 129: Cadila's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 130: Cancer Research Technology's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 131: Cell Genesys’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 132: Celldex Therapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 133: CG Therapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 134: Cosmo Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 135: CSL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 136: Dendreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 137: DeveloGen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 138: Eisai's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 139: Eli Lilly's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 140: EntreMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 141: Epeius Biotechnologies’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 142: Generex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 143: GenOdyssee Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 144: GENTICEL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 145: Geron's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 146: GlaxoSmithKline's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 147: Gliknik's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 148: GlobeImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 149: Gradalis’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 150: Ichor Medical Systems’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 151: Idera Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 152: ImmunoCellular Therapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 153: ImmunoFrontier's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 154: Immunotope's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 155: Innate Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 156: Inovio's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 157: Introgen Therapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 158: ISA Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 159: Johnson & Johnson's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 160: Medical Marketing International's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 161: MediGene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 162: Menarini's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 163: Merck KGaA's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 164: Micromet's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 165: MolMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 166: Mologen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 167: Nemod Biotherapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 168: Neovacs’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 169: NIH's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 170: Non-industrial Sources' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 171: Northwest Biotherapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 172: NovaRx's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 173: OncoMune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 174: OncoTherapy Science's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 175: Oncothyreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 176: Oncovir's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 177: Onyvax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 178: Oxford BioMedica's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 179: Pepscan Systems’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 180: Pepscan Therapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 181: Pfizer's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 182: Pharmexa's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 183: Prima Biomed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 184: Progenics Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 185: Protherics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 186: Radient Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 187: Receptor BioLogix's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 188: responsif's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 189: Sanofi-Aventis’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 190: Scancell's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 191: SciClone Pharmaceuticals’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 192: TapImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 193: Therion Biologics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 194: Transgene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 195: United Biomedical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 196: Vaccinex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 197: Vaxil BioTherapeutics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 198: Vaxon Biotech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 199: VaxOnco's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 200: Vectura's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 201: Vical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 202: Viragen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 203: Virionics’ Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 204: ViroMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out
Table 205: Zensun's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out

- AC Immune
- Adaptimmune
- Aduro BioTech
- Advaxis
- Aida Pharmaceuticals
- Akela Pharma
- AlphaVax
- Apthera
- Astellas
- AstraZeneca
- AVI BioPharma
- Bavarian Nordic
- Bellicum Pharmaceuticals
- Biogen Idec
- Biostar
- BioVex
- Cadila
- Cancer Research Technology
- Cell Genesys
- Celldex Therapeutics
- CG Therapeutics
- Cosmo Pharmaceuticals
- CSL
- Dendreon
- DeveloGen
- Eisai
- Eli Lilly
- EntreMed
- Epeius Biotechnologies
- Generex
- GenOdyssee Pharmaceuticals
- GENTICEL
- Geron
- GlaxoSmithKline
- Gliknik
- GlobeImmune
- Gradalis
- Ichor Medical Systems
- Idera Pharmaceuticals
- ImmunoCellular Therapeutics
- ImmunoFrontier
- Immunotope
- Innate Pharma
- Inovio
- Introgen Therapeutics
- ISA Pharmaceuticals
- Johnson & Johnson
- Medical Marketing International
- MediGene
- Menarini
- Merck KGaA
- Micromet
- MolMed
- Mologen
- Nemod Biotherapeutics
- Neovacs
- NIH – US National Institute of Health
- Non-industrial Sources
- Northwest Biotherapeutics
- NovaRx
- OncoMune
- OncoTherapy Science
- Oncothyreon
- Oncovir
- Onyvax
- Oxford BioMedica
- Pepscan Systems
- Pepscan Therapeutics
- Pfizer
- Pharmexa
- Prima Biomed
- Progenics Pharmaceuticals
- Protherics
- Radient Pharmaceuticals
- Receptor BioLogix
- responsif
- Sanofi-Aventis
- Scancell
- SciClone Pharmaceuticals
- TapImmune
- Therion Biologics
- Transgene
- United Biomedical
- Vaccinex
- Vaxil BioTherapeutics
- Vaxon Biotech
- VaxOnco
- Vectura
- Vical
- Viragen
- Virionics
- ViroMed
- Zensun

Customers who bought this item also bought

• Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
• Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
• Cancer Vaccine Partnering Terms and Agreements
• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
• Personalized Medicine - Scientific and Commercial Aspects
• Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
• Global Oncology Drug Pipeline Capsule – 2012
• Antibody Drug Target Atlas in Oncology
• Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries.